ERBB2 and breast cancer: BC subtype guides the standard systemic therapy administered, which consists of endocrine therapy for all HR + tumors (with some patients requiring chemotherapy as well), trastuzumab-based HER2-directed antibody therapy plus chemotherapy for all HER2 + tumors (with endocrine therapy given in addition, if concurrent HR positivity), and chemotherapy alone for the triple-negative subtype.